Medicine and Dentistry
Venous Thromboembolism
100%
Thrombosis
83%
Anticoagulation
65%
Menorrhagia
40%
Phlebothrombosis
32%
Hormone Therapy
25%
Thrombocytopenia
25%
Myelofibrosis
23%
Uterus Bleeding
23%
Bleeding
22%
Antithrombotic
22%
Patient Population
19%
Sulfhemoglobinemia
17%
Hematologic Malignancy
16%
Direct Oral Anticoagulant
13%
Decision Making
13%
Meta-Analysis
13%
Systematic Review
13%
Ruxolitinib
11%
Breast Reconstruction
11%
Maternal Death
11%
Laboratory Test
11%
Cardiovascular System
11%
Triage
11%
Transplantation
11%
Adolescent
11%
Acute Pulmonary Embolism
11%
Blood Stasis
11%
Adverse Outcome
11%
Polycythemia vera
11%
Malignant Neoplasm
11%
International Prognostic Scoring System
11%
Hematopoietic Stem Cell
11%
Biological Marker
11%
Superficial Thrombophlebitis
11%
Chronic Pain
11%
Cell Transplantation
11%
Heparin-Induced Thrombocytopenia
11%
Ovarian Vein
11%
Contraceptive Agent
11%
Recurrent Disease
10%
Anticoagulant Therapy
10%
Anticoagulant
9%
Deep Vein Thrombosis
9%
Iron Deficiency
9%
Hormone Substitution
9%
Sentinel Lymph Node
8%
Neoplasm
8%
Platelet
8%
Menstruation
8%
Pharmacology, Toxicology and Pharmaceutical Science
Venous Thromboembolism
92%
Menorrhagia
64%
Anticoagulant Agent
56%
Bleeding
52%
Thrombosis
48%
Uterus Bleeding
32%
Rivaroxaban
29%
Apixaban
25%
Myelofibrosis
23%
Direct Oral Anticoagulant
22%
Warfarin
18%
Contraceptive Agent
16%
Hematologic Malignancy
16%
Lung Embolism
15%
Iron Deficiency
15%
Thrombocytopenia
14%
Disease
13%
Biological Marker
11%
Maternal Death
11%
Polycythemia vera
11%
Heparin Induced Thrombocytopenia
11%
Ruxolitinib
11%
Thrombophlebitis
11%
Blood Stasis
11%
Bleeding Disorder
11%
Thrombocyte Factor 4
11%
Adverse Outcome
11%
Anagrelide
11%
Anemia
9%
Vein Thrombosis
9%
P-Selectin
9%
Recurrent Disease
8%
Low Molecular Weight Heparin
8%
Medroxyprogesterone Acetate
8%
Deep Vein Thrombosis
7%
Antithrombotic Therapy
7%
Haemophilia
7%
Von Willebrand Disease
7%
Endocrine Therapy
7%
Cohort Study
7%
Hormone Cancer Therapy
6%
Postpartum Hemorrhage
5%
Hematologic Disease
5%
Mortality Rate
5%
Symptom
5%
Overall Survival
5%
Recurrence Free Survival
5%
Randomized Controlled Trial
5%
Blood Clotting Factor 8
5%
Comorbidity
5%
Keyphrases
Abnormal Uterine Bleeding
75%
Venous Thromboembolism
42%
Anticoagulation
40%
Thrombosis
34%
Oral Anticoagulants
30%
Rivaroxaban
28%
Apixaban
25%
Anticoagulants
24%
Anticoagulant Therapy
20%
Patient Demographics
19%
Warfarin
17%
Bleeding
17%
Quality of Life
16%
Meta-analysis
13%
Direct Oral Anticoagulants
13%
Low Molecular Weight Heparin
12%
Immediate Breast Reconstruction
11%
Thrombocytopenia
11%
Postmastectomy Radiation Therapy
11%
Estrogen
11%
Acute PE
11%
Hestia
11%
SPESI
11%
Spirituality
11%
Cancer-associated Thrombosis
11%
Radiation Therapy
11%
Blood Disorders
11%
Ruxolitinib
11%
Polycythemia Vera
11%
Collaborative Care
11%
Laboratory Biomarkers
11%
Myelofibrosis
11%
Challenging Patients
11%
Menstruation
11%
Pregnant Women
11%
Anagrelide
11%
Lactation
11%
Persistent Fever
11%
Ovarian Vein Thrombosis
11%
Acute Vascular Events
11%
Thrombosis in Pregnancy
11%
Use Case Study
11%
Anticoagulation Stewardship
11%
Hormonal Therapy
11%
Thrombosis Risk
9%
Major Bleeding
9%
Female Patients
9%
Management Strategy
9%
Iron Deficiency
9%
Recurrent Venous Thromboembolism
8%
